FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/07/2026
Voltar para busca
Dado oficial do USPTO
PNEOO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PNEOO
ST13
US500000079407300Classe
1, 5, 40, 42
Pedido
79407300
Registro
8226523
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
28/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 40, 42
Data de depósito
08/08/2024
Data de registro
28/04/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/04/2026
Última transação
28/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
26
Localização do titular
BE
Examinador
PEISECKI, MARK A
Unidade examinadora
L50
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
PNEOO B.V.
Representantes
Cheryl L. Burbach Erise IP, P.A.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Biological preparations for use in cell culturesother than for medical or veterinary purposesfor boosting cells in the immune system for improved therapies; biological preparations for use in cell culturesin the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents in the nature of complexes of molecules for scientific research and for clinical and industrial use; proteins for use in scientific research; regulatory proteins in raw material for scientific research; the aforementioned goods solely related to respiratory and pulmonary diseasesincluding lung cancer
Classe 5
Medicalbiologicalpharmaceutical preparations for the treatment of pulmonary diseases; veterinary preparations for petscattlelivestock for preventing and treating infectious diseasesmedical disordersdiseaseslung cancer; medicalbiologicalpharmaceutical preparations for preventing and treating infectious diseasesmedical disordersdiseaseslung cancer; medicalbiologicalpharmaceutical preparations for preventing and treating viralbacterialyeast infections; veterinary preparations for petscattlelivestock for preventing and treating viralbacterialyeast infections; medicalbiologicalpharmaceutical preparations for preventing and treating cancermetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; veterinary preparations for petscattlelivestock for preventing and treating cancermetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; vaccines; regulatory proteins for medical useprotein arrays for medical diagnosis purposesthe foregoing solely related to respiratory and pulmonary diseasesincluding lung cancer; pharmaceutical compounds being a component in pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the prevention of diseases of the respiratory system; diagnostic preparations for medical purposesthe foregoing solely related to respiratory and pulmonary diseasesincluding lung cancer; chemical diagnostic reagents for medical usethe foregoing solely related to respiratory and pulmonary diseasesincluding lung cancer
Classe 40
Provision of informationadvice and consultancy services in the fields of cell therapygene editingprotein replacementantibodiesthe aforementioned services solely related to respiratory and pulmonary diseasesincluding lung cancer
Classe 42
Medical research services for the treatment of various medical disorderscancerpulmonary diseasesrespiratory diseasesinfectious diseases; Scientific laboratory services; scientific research for medical purposes in the area of diseases; scientific research in the field of genetics and genetic engineering; genetic research for scientific research purposes; genetic mapping for scientific purposes; DNA screening for scientific research purposes; DNA analysis services for scientific research purposes; providing scientific research information in the field of medical disorders and their treatment; biotechnological research relating to enzymatic synthesis; toxicity testing for scientific research purposes; toxicity analysis for scientific research purposes; software as a service (SaaS) featuring artificial intelligence software for use in database management relating to the medical field; software as a service (SaaS) featuring software for use in data base management relating to the medical field; all of the aforementioned services solely related to respiratory and pulmonary diseasesincluding lung cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
28/04/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
28/04/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/04/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/04/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/04/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
13/04/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
13/04/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
09/04/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/03/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
23/03/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/03/2026
PUBO
PUBLISHED FOR OPPOSITION
10/03/2026
GPNX
NOTIFICATION PROCESSED BY IB
05/03/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/03/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/02/2026
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
17/02/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/02/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/12/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/12/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/12/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/11/2025
RFNT
REFUSAL PROCESSED BY IB
07/11/2025
CNRT
NON-FINAL ACTION WRITTEN
09/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/09/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/09/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/09/2025
RFNT
REFUSAL PROCESSED BY IB
12/04/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/03/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/03/2025
RFRR
REFUSAL PROCESSED BY MPU
27/03/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/02/2025
CNRT
NON-FINAL ACTION WRITTEN
20/02/2025
DOCK
ASSIGNED TO EXAMINER
13/02/2025
MAFR
APPLICATION FILING RECEIPT MAILED
24/10/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/10/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/10/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PNEOO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.